Brenntag Pharma unveiled BYPHAR, the new regulated biopharma manufacturing brand

• BYPHAR is built to meet the stringent requirements of modern biopharmaceutical processes
• With BYPHAR Brenntag integrates the expertise of several long-standing industry leaders like Budenheim, Citribel, K+S and Kerry into the product range.

23 April 2026 -- Essen, Germany -- Brenntag, the global market leader in chemicals and ingredients distribution, unveiled BYPHAR yesterday in an online live press event. A recording can be found here: brenntag.gomexlive.com/livestream/ and all details on the BYPHAR product range are available at brenntag.com/byphar.

BYPHAR is Brenntag’s new specialized biopharma brand, designed to bring quality, efficiency and flexibility to every stage of biopharmaceutical manufacturing. BYPHAR unifies Brenntag’s high quality raw materials, advanced facilities, and value added services into a comprehensive, regulatory ready portfolio supporting customers from early development through to commercial production.

BYPHAR is Brenntag’s solution specifically designed for use by Biopharma companies, helping their manufacturing process to shift from transactional supplier relationships towards a holistic, curated, compliant portfolio, streamlining complexity, accelerate timelines, and ultimately help bring more effective therapies to patients faster.

BYPHAR provides a dependable gateway into highly regulated markets. The portfolio is backed by Brenntag’s global distribution network, long standing industry trust, and deep technical expertise – ensuring secure supply, consistent documentation, and full regulatory compliance.

BYPHAR is engineered to support innovators, emerging biotech companies, CDMOs, vaccine manufacturers, biosimilar producers, and diagnostic companies across a wide range of manufacturing processes, including mAbs, Recombinant proteins, Cell & gene therapies, Vaccines, Nucleic acid–based production (mammalian or microbial), ADC manufacturing.

Gearoid O’Rourke, Senior Director Biopharma, Brenntag Pharma, states:“BYPHAR represents a major step forward in how we support our biopharma customers. By combining high quality raw materials and flexibility with global supply reliability and deep regulatory expertise, we are helping customers accelerate development and ensure the highest standards of all manufacturing stages.”

The brand’s raw materials are organized into three clearly defined categories, which will be available from July 2026 on. Each is tailored to specific risk levels and development stages:

• BYPHAR Explore – Non GMP materials for early phase development, R&D, and non critical applications. Monograph compliant where applicable, with essential regulatory documentation
• BYPHAR Enhance – GMP compliant materials suitable for all biopharmaceutical manufacturing stages, following IPEC and EXCiPACT guidelines and offering full regulatory ready documentation
• BYPHAR Excel – LBLE critical raw materials for high risk applications, produced under GMP conditions, multicompendial where applicable, and supported by extensive regulatory documentation.

This structured approach enables customers to select the right material grade for each stage of development, accelerating qualification and regulatory readiness. The BYPHAR portfolio also includes co branded products manufactured in partnership with globally recognized producers, ensuring exceptional purity, consistency, and supply reliability. BYPHAR integrates the expertise of several long standing industry leaders:

• Budenheim – High purity phosphates with rigorous impurity control and multi pharmacopoeia compliance
• Citribel – Sustainable, high volume production of citric acid and citrates with over a century of manufacturing expertise
• K+S – Reliable, pharmaceutical grade salts produced from proprietary NaCl and KCl resources
• Kerry – High quality acetates manufactured under strict cGMP standards for critical biopharmaceutical applications.

These partnerships strengthen BYPHAR’s ability to deliver consistent, regulatory ready materials at global scale.

BYPHAR reflects Brenntag’s commitment to quality excellence, customer centricity, integrity, and reliability. Key differentiators include:

• Full control of the supply chain through Brenntag’s own label offering
• A global distribution network enabling faster lead times
• Co branded partnerships with world class manufacturers
• A complete portfolio supporting early stage to commercial manufacturing
• High quality materials with GMP/GDP compliance and regulatory readiness
• Flexible, customer focused service backed by technical expertise.

About Brenntag
Brenntag is the global market leader in chemicals and ingredients distribution. The company holds a central role in connecting customers and suppliers of the chemical industry. Headquartered in Essen, Germany, Brenntag has more than 17,300 employees worldwide and operates a network of around 600 sites in more than 70 countries. In 2025, Brenntag generated sales of 15.2 billion EUR. The two global divisions, Brenntag Essentials and Brenntag Specialties, provide a diversified and broad portfolio of industrial and specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, comprehensive regulatory know-how, and digital solutions for a wide range of industries. Brenntag pursues an ambitious sustainability agenda and is committed to sustainable solutions in its own sector and the industries served. Brenntag shares have been listed at the Frankfurt Stock Exchange since 2010, in the DAX since September 2021. In addition, the Brenntag SE shares are listed in the DAX 30 ESG and DAX ESG Target. For more information, visit www.brenntag.com.

About Brenntag Pharma
Brenntag Pharma leverages this global backbone to deliver high quality pharmaceutical ingredients, formulation support, regulatory expertise and value-added services, from early stages development to commercial manufacturing, to pharma and biopharma landscape. With a commitment to safety, innovation, and supply chain excellence, Brenntag Pharma plays a vital role in enabling safer, compliant, and innovative healthcare solutions. Visit: brenntag.com/en-be/industries/pharma